Results 311 to 320 of about 61,821 (357)

Bispecific human IgG by design

Journal of Immunological Methods, 2001
A major obstacle facing the development of bispecific antibodies as therapeutics has been the formidable task of producing these complex molecules in sufficient quantity and purity for clinical trials. These production difficulties have been largely overcome with the advent of efficient methods for the secretion of designer bispecific antibody ...
Paul J Carter
exaly   +3 more sources

Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies

2019
Bispecific antibodies are an emerging novel therapeutic construct used to treat a variety of cancers. These drugs utilize a small fusion protein to link two single-chain antibodies, allowing for simultaneous binding of two different epitopes. Bispecific T-cell engagers (BiTE) are a subset of bispecific antibodies that bind the target antigen on the ...
Stacy L. Cooper, Patrick A. Brown
openaire   +1 more source

Bispecific antibodies for the treatment of hemophilia A

Expert Opinion on Biological Therapy, 2021
Emicizumab is a bispecific antibody exerting cofactor function of FVIIIa irrespective of the presence of FVIII inhibitors. Long-term data of phase 1/2 and phase 3 studies have been accumulated. Various questions such as indicated patients, ITI, application to PUPs, hemostatic treatment including surgeries, and emicizumab-related morbidity remain to be ...
openaire   +2 more sources

Immunotherapeutic perspective for bispecific antibodies

Immunology Today, 2000
Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy.
A B, van Spriel, H H, van Ojik, J G, van De Winkel   +2 more
openaire   +2 more sources

Fine-tuning bispecific therapeutics

Pharmacology & Therapeutics, 2020
Bispecific therapeutics target two distinct antigens simultaneously and provide novel functionalities that are not attainable with single monospecific molecules or combinations of them. The unique potential of bispecific therapeutics is driving extensive efforts to discover synergistic dual targets, design molecular formats to integrate bispecific ...
openaire   +2 more sources

Bispecific antibodies in oncology

Nature Reviews Drug Discovery, 2022
Arman, Esfandiari, Sorcha, Cassidy, Rachel M, Webster   +2 more
openaire   +2 more sources

Catumaxomab: A bispecific trifunctional antibody

Drugs of Today, 2009
The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells.
M, Sebastian, A, Kuemmel, M, Schmidt, A, Schmittel   +3 more
openaire   +2 more sources

Bispecific antibodies for delivery into the brain

Current Opinion in Chemical Biology, 2013
The blood-brain barrier (BBB) is a formidable obstacle preventing drug delivery to the brain, particularly for large protein therapeutics. The utilization of endogenous brain endothelial transport pathways, however, represents a promising approach to cross the cellular barrier through receptor-mediated transcytosis.
Ryan J, Watts, Mark S, Dennis
openaire   +2 more sources

Bispecific antibody therapy for lymphoma

Best Practice & Research Clinical Haematology
The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL.
Genevieve M, Gerhard, Gottfried, von Keudell   +1 more
openaire   +2 more sources

Bispecific antibodies.

Critical reviews in immunology, 1993
Bispecific antibodies--molecules combining two different antigenic specificities--are currently being developed as new agents for immunotherapy and for basic studies in cell biology. Bispecific antibodies (BsAb) are prepared by chemically linking two different monoclonal antibodies or by fusing two hybridoma cell lines to produce a hybrid-hybridoma ...
M W, Fanger, P M, Morganelli, P M, Guyre
openaire   +1 more source